BRNS (Barinthus Biotherapeutics) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Barinthus Biotherapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Barinthus Biotherapeutics's Free Cash Flow for the three months ended in Dec. 2024 was $12.81 Mil. Barinthus Biotherapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Barinthus Biotherapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Barinthus Biotherapeutics's current FCF Yield % is -108.44%.

The historical rank and industry rank for Barinthus Biotherapeutics's FCF Margin % or its related term are showing as below:

BRNS' s FCF Margin % Range Over the Past 10 Years
Min: -12585.45 Med: -234.83 Max: -46.01
Current: -199.29

During the past 6 years, the highest FCF Margin % of Barinthus Biotherapeutics was -46.01%. The lowest was -12585.45%. And the median was -234.83%.

BRNS's FCF Margin % is ranked worse than
56.49% of 1009 companies
in the Biotechnology industry
Industry Median: -128.43 vs BRNS: -199.29

Barinthus Biotherapeutics FCF Margin % Historical Data

The historical data trend for Barinthus Biotherapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Barinthus Biotherapeutics FCF Margin % Chart

Barinthus Biotherapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-234.83

-12,585.45

-46.01

-7,024.69

-199.29

Barinthus Biotherapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-122.33	-

Competitive Comparison of Barinthus Biotherapeutics's FCF Margin %

For the Biotechnology subindustry, Barinthus Biotherapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Barinthus Biotherapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Barinthus Biotherapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Barinthus Biotherapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Barinthus Biotherapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-29.832	/	14.969
	=	-199.29 %

Barinthus Biotherapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	12.808	/	0
	=	%

Barinthus Biotherapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Barinthus Biotherapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Barinthus Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Barinthus Biotherapeutics PLC (NAS:BRNS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 6-10, Rutherford Avenue, Zeus Building, Harwell, GBR, OX11 0DF

Website

https://www.barinthusbio.com

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.

Executives

Joseph Scheeren	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Robin Wright	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
William Enright	director, officer: Chief Executive Officer	910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Nadege Pelletier	officer: Chief Scientific Officer	C/O VACCITECH PLC, UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Gemma Brown	officer: Chief Financial Officer	VACCITECH PLC, UNIT 6-10, ZEUS BUILDING, RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Graham Griffiths	officer: Chief Business Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Christopher Ellis	officer: Chief Operating Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Anne M. Phillips	director	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Oxford Science Enterprises Plc	10 percent owner	46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT
Karen A Dawes	director	579 BELLEVUE AVE, NEWPORT RI 02840
Pierre A. Morgon	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Margaret Marshall	officer: Chief Medical Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Thomas George Evans	officer: Chief Scientific Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Alex Hammacher	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Georgy Egorov	officer: Chief Financial Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE